Background: To compare the acute gastrointestinal (GI) and genitourinary (GU) toxicity profiles between intensity-modulated radiotherapy (IMRT) and three-dimensional conformal radiotherapy (3DCRT) in rectal cancer patients treated with neoadjuvant chemoradiation (NCRT) using metaanalysis and pooled-analysis from published articles. Methods: Literature search was performed in PubMed and EMBASE from inception to March 2017. The odd ratios (ORs) were calculated and random effects model was used for meta-analysis. Chisquare or Fisher's exact test was performed for the pooled-analysis. Results: Six studies including a total of 859 patients met the inclusion criteria. Most patients (98.7%) received NCRT. In the meta-analysis, IMRT reduced grade ≥ 2 acute overall GI toxicity, diarrhea and proctitis with ORs of 0.38, 0.32 and 0.60, respectively (all P < 0.05), compared to 3DCRT. IMRT also reduced acute grade ≥ 3 proctitis compared to 3D-CRT (OR, 0.24; P = 0.03). No significant heterogeneity or publication bias was detected. In the pooled-analysis, IMRT reduced the incidence of grade ≥ 2 acute overall GI toxicity, diarrhea, proctitis and GU toxicity (all P < 0.05). Moreover, lower incidence of grade ≥ 3 acute overall GI toxicity, diarrhea and proctitis were observed in the patients treated with IMRT (all P < 0.05).
Introduction
Neoadjuvant chemoradiation (NCRT) with pelvic radiotherapy (RT) and concurrent 5-fluorouracil (FU)-based chemotherapy is the standard treatment for locally advanced rectal cancer (LARC) with clinically ≥ T3 or node-positive disease (1) (2) (3) (4) (5) . Although the rates of acute treatment-related toxicities seem to be reduced due to the shift from adjuvant to the neoadjuvant setting (1), acute toxicity due to NCRT is still a limiting factor for compliance to treatment and the quality of life in patients with LARC (6, 7) . Phase III prospective trials have reported that 15-40% of patients experience grade ≥ 3 acute toxicity during NCRT for LARC (1) (2) (3) (4) .
Intensity-modulated radiotherapy (IMRT), due to its ability to deliver a highly conformal RT plan with steep dose-gradients between the tumor and normal tissues, has been frequently adopted for various malignancies of the pelvis (8) (9) (10) . However, the significant benefit of IMRT over three-dimensional conformal radiotherapy (3DCRT) in terms of toxicity and outcome in NCRT for LARC remains to be proven. No Phase III trial has addressed it to date. Acute gastrointestinal (GI) toxicity, especially diarrhea and enteritis, has been shown to have a close dose-volume relationship with the irradiated small bowel (11) (12) (13) . IMRT may be considered as a potential standard for NCRT in LARC regarding the dosimetric benefit of IMRT for the small bowel/ bladder (13) (14) (15) (16) , and the clinical evidence of reduced toxicity (17) (18) (19) (20) (21) (22) (23) .
However, the retrospective nature and small number of patients included in those studies (17) (18) (19) (20) (21) (22) (23) hamper the direct embracement of the studies' results.
To overcome the limitation of small retrospective series and establish the clinical benefit of IMRT in LARC patients undergoing NCRT, we compared the acute toxicity profiles between IMRT and 3DCRT based on published literature using meta-analysis and pooled-analysis from available patient data.
Methods

Study selection
Two radiation oncologists (C.W.W. and H.C.K.) performed a comprehensive literature search via electronic databases, EMBASE and PubMed, using various combinations of keywords from their earliest available date to 24 March 2017 (Fig. 1) . Only English-written abstracts were independently reviewed by two authors. Studies displaying the comparison of toxicity profiles between IMRT vs. 3DCRT in rectal cancer patients were selected. The followings were excluded after review: (1) case reports and review articles; (2) abstracts without original articles; (3) studies without a comparison group regarding RT technique; (4) studies with insufficient toxicity profiles to calculate the odds ratio (OR) of toxicity between IMRT and 3DCRT. After a thorough review by two authors mentioned above, seven studies (17-23) met the inclusion criteria. The name of authors, institutions, nations and treatment period of the studies were reviewed again to check for duplication of patient cohorts. The patients from the study by Yang et al. (17) was highly suspicious for duplicated inclusion in a more recent study by Ng et al. (22) , and therefore, was excluded in the final analysis after discussion with the corresponding author of both studies via e-mail.
Data extraction
Data were independently extracted by two authors (C.W.W. and H.C.K.). ORs between IMRT and 3DCRT regarding the incidence of reported acute grade ≥ 2 and grade ≥ 3 overall GI toxicity, diarrhea, proctitis and overall genitounrinary (GU) toxicity were calculated in each study with available data. Furthermore, since all six studies selected for the final analysis evaluated acute toxicities according to the Common Terminology Criteria for Adverse Events version 3.0 (18) (19) (20) (21) (22) (23) , available data from each study was merged for pooled-analysis.
Individual patient data of all six studies were requested through e-mail, and the corresponding authors of Ng et al. (22) and Huang et al. (23) provided the requested data. Although data for overall incidence of any GI toxicity was missing in the original article by Ng et al., it was available after the individual patient data was provided to us (22) . Information of acute diarrhea and proctitis was also not reported by Huang et al., but was available in the final analysis after obtaining the individual patient data (23) .
Statistical analysis
In the meta-analysis, the OR for the incidence of each acute toxicity between IMRT and 3DCRT was the primary endpoint. Since no randomized study was available to date, the Risk of Bias Assessment Tool for Nonrandomized Studies was used (24) . For each study, the pooled OR with 95% confidence interval (CI) was calculated using the randomeffects model weighted by inverse variance method and is presented as a forest plot. The heterogeneity among the studies was assessed by the χ 2 -test-based Q-statistics, and the degree of heterogeneity was estimated with the I 2 statistic. A P < 0.10 by Q-statistics or I 2 > 50% indicated significant heterogeneity between the studies. Potential publication bias was assessed using funnel plots and Egger's test, and P < 0.05 was considered to represent a statistically significant bias. All statistical analysis for the meta-analysis was performed using the R-package, version 3.3.3 (http://www.r-project.org/). Pooled analysis was done by SPSS version 23.0 (IBM SPSS, Armonk, USA). Number of events and the total number of patients treated by IMRT versus 3DCRT were extracted from studies reporting the corresponding toxicity data and were merged. Chi-square test or the Fisher's exact test was used to compare the incidence of toxicities between IMRT and 3DCRT. The threshold for statistical significance was P < 0.05. As a secondary endpoint regarding efficacy, we additionally compared the rates of pathological complete response (pCR) in patients treated with NCRT plus surgery between the two RT techniques using pooled analysis.
Results
Study characteristics
From PubMed and EMBASE, 1509 studies were identified with 202 duplicates according to the aforementioned strategy for literature search. Using titles and abstracts, 1259 studies were excluded after carefully screening the titles and searching for English-written full-texts. Forty-eight studies were thoroughly reviewed with full-text articles and six of them were finally selected for analysis ( Fig. 1) .
A total of 859 rectal cancer patients were identified from the six retrospective clinical studies (18) (19) (20) (21) (22) (23) (Table 1) . Of those patients, only 11 patients (1.3%) from the study by Samuelian et al. (19) were treated by postoperative chemoradiation whereas 848 (98.7%) were treated by NCRT. Overall, 98.5% (404/410) and 98.9% (444/449) were treated with NCRT in IMRT and 3DCRT group, respectively. About half of the patients were treated by IMRT (47.7%, 410/859) and the RT dose were 45-50. 4 Gy with conventional fractionation in all studies (Table 1) . Concurrent 5-FU-based chemotherapy was used in all patients, and 53.5% (161/301) of the patients from one study (22) were treated with induction chemotherapy composed of 5-FU-based chemotherapy plus oxaliplatin prior to RT.
Meta-analysis
In the meta-analysis, 4, 4, 5 and 5 studies were available for comparison of IMRT and 3DCRT regarding acute grade ≥ 2 overall GI, diarrhea, proctitis and overall GU toxicity, respectively (Fig. 2) . IMRT, compared to 3DCRT, significantly reduced overall GI, diarrhea and proctitis with a pooled ORs of 0.38 (95% CI, 0.26-0.54; P < 0.01), 0.32 (95% CI, 0.20-0.50; P < 0.01) and 0.60 (95% CI, 0.42-0.86; P < 0.01), respectively. For grade ≥ 3 overall GI, diarrhea, proctitis and overall GU toxicity, 3, 3, 2 and 3 studies were included, respectively (Fig. 3) . The study by Ng et al. (22) could not be included for analysis of grade ≥ 3 proctitis and overall GU toxicity since no event occurred in both IMRT and 3DCRT arms. Only acute proctitis was significantly reduced with IMRT (OR, 0.24; 95% CI, 0.07-0.84; P = 0.03). No significant publication bias was found for each endpoint according to the Egger's test (Fig. 4) .
Pooled-analysis
The included studies and number of patients for each endpoint as well as the results of pooled-analysis are shown in Table 2 . IMRT demonstrated significantly lower rates of every toxicity endpoint compared to 3DCRT except for grade ≥ 3 GU toxicity (all P < 0.05). However, even grade ≥ 3 overall GU toxicity showed a non-significantly favorable trend towards IMRT (P = 0.069). In terms of pCR rate, there was no significant statistical difference between IMRT and 3DCRT (19.4 vs. 16.7%, respectively; P = 0.390) ( Table 3 ). Figure 2 . Forest plots and odds ratios for acute grade ≥ 2 (A) overall GI toxicity, (B) diarrhea, (C) proctitis and (D) overall GU toxicity. An odds ratio below 1.0 and a P < 0.05 (overall effect) indicates a significant favor for IMRT compared to 3DCRT. CI, confidence interval; IMRT, intensity-modulated radiotherapy; 3DCRT, 3-dimensional conformal radiotherapy.
Discussion
The potential benefit of IMRT in LARC is due to its highly conformal dose distribution to the RT target, allowing dose reduction to the small bowel and other organs at risk. However, although its clinical benefit over conventional 3DCRT has not been validated through randomized trials, IMRT has been adopted in a number of prospective Phase I/II trials testing various dose-regimens with concurrent 5-FU-based chemotherapy, mainly capecitabine (25) (26) (27) (28) (29) . Only several retrospective studies support the clinical conversion of the theoretical benefit of IMRT compared to 3DCRT in LARC (17) (18) (19) (20) (21) (22) (23) . Furthermore, to the authors' knowledge, there is only one ongoing prospective randomized Phase II trial from Ireland (NCT02151019) comparing IMRT and 3DCRT with grade ≥ 2 toxicity as the primary endpoint. Therefore, there is no strong evidence to recommend IMRT routinely in LARC treated by NCRT. However, the use of IMRT is increasing throughout time (30) and newly launched clinical trials prefer the use IMRT as part of the protocol. Therefore, we performed a meta-analysis and pooled-analysis upon available data to strengthen the clinical evidence supporting IMRT. Since all studies used concurrent 5-FU-based chemotherapy (18) (19) (20) (21) (22) (23) , the issue of chemotherapy attributing to acute GI toxicity will not be further discussed in this article.
The lack of evidence from randomized Phase III trial made a metaanalysis based on retrospective studies or a pooled-analysis based on a large number of patients necessary. In our meta-analysis, IMRT showed superior outcomes for acute grade ≥ 2 overall GI toxicity, diarrhea and proctitis (Fig. 2) . It also showed benefit in terms of acute grade ≥ 3 proctitis (Fig. 3) . However, the number of studies included in metaanalysis for each endpoint was small because the reported outcomes regarding grade of toxicity (e.g., acute diarrhea: grade ≥ 2 [19] vs. grade ≥ 3 [18] ) or endpoint differed among studies (e.g., overall GI toxicity [23] vs. diarrhea/nausea/vomiting [19] ). Nevertheless, all studies that met our inclusion criteria have assessed the acute toxicities according to the Common Terminology Criteria for Adverse Events version 3.0. Therefore, we also planned for a pooled-analysis in a multi-institutional study fashion. Pooled-analysis based on~300 patients in each arm of each endpoint was performed, and IMRT was shown significantly favorable in terms of every acute grade ≥ 2 and grade ≥ 3 toxicity analyzed (Table 2 ), whereas no difference in pCR rates were observed ( Table 3 ). The uniformity of utilized RT dose or chemotherapy regimen makes these analyses reliable despite its retrospective nature.
The relationship between RT dose to the small bowel and acute GI toxicities such as diarrhea, nausea and vomiting (N/V) is well established (11) (12) (13) 31) . Dosimetric studies have confirmed the benefit of IMRT compared to 3DCRT over the past decade in whole-pelvic RT plans for rectal cancer (13) (14) (15) (16) (23) also confirmed that the volume of the small bowel receiving 15, 30 and 40 Gy was significantly smaller in IMRT plans, and the difference became larger in higher dose levels. According to the results of our study, these dosimetric advantages of sparing the small bowel with IMRT seem to have successfully converted into a clinical benefit by reducing the incidence of acute diarrhea. Although not specifically analyzed in our study, the incidence of grade ≥ 2 N/V in the individual patient data from Ng et al. was 0.3% indicating an extremely low incidence (22) . Samuelian et al. (19) and Parekh et al. (20) also reported a 0% incidence of grade ≥ 2 N/V in patients treated by IMRT.
RT-related acute proctitis is an inflammatory process of the rectal mucosa that can manifest as symptoms such as mucous discharge, cramps, nausea, diarrhea, urgency, tenesmus, or bleeding. The microvillus structure is damaged accompanied by hyperemia and ulceration microscopically. In rectal cancer patients receiving NCRT, the portion of rectum included in the high-dose target volume should not differ between IMRT and 3DCRT plans since the policy of target volume delineation are identical between the two methods (32, 33) . Therefore, the incidence of proctitis in both methods should not have a significant difference theoretically. Indeed, Arbea et al. reported no difference in D 5% and V 40 Gy of the rectum between IMRT and 3DCRT planning (14) . However, the incidence of acute proctitis was found to be significantly lower in patients treated with IMRT according to our results, and several hypotheses may explain this finding. First, with increased dose-homogeneity by IMRT, the necessary mean dose of the planning target volume, which normally encompasses the rectum, can be slightly, but significantly lowered ensuring a same coverage of the target volume compared to 3DCRT (13, 16) . Second, the more sensitive nature of IMRT to geometric errors such as set-up errors, daily variation of the rectum volume, or interfractional rectal movement, compared to 3DCRT (34), may have canceled-out the effects of overdosed areas of the rectum, so-called 'hot-spots', throughout the treatment course of 25-28 fractions. Acute reactions of the rectum including proctitis are known to be closely correlated with the volume of rectum receiving ≥ 50 Gy or ≥ 60 Gy (35) , which corresponds to the dose of hot spots for rectal cancer patients receiving conventionally fractionated RT as a part of NCRT. However, the finding of reduced proctitis may be only a result of several biases such as inter-physician variation of target contouring, RT-planning objectives (e.g., V 95% vs. V 100% ), policy of limiting the maximum or minimum dose to the planning target volume, etc. Variations in image-guidance techniques used by institutions or physicians for each technique also can contribute to the bias.
Acute GU toxicity, mostly represented as RT-induced cystitis is usually diagnosed by the presence of minor, irritative, and temporary voiding symptoms or painless, microscopic hematuria. Although not much studied in rectal cancer, data from other cancers of the pelvis such as prostate, cervix or bladder itself indicate a dose-volume relationship between acute bladder injury and RT (36, 37) . No difference between IMRT and 3DCRT was observed in our meta-analysis. However, in the pooled-analysis performed by Chi-square test, significant reduction of acute grade ≥ 2 overall GU toxicity as well as a non-significant trend favoring IMRT for acute grade ≥ 3 overall GU toxicity was observed. The incidence of acute grade ≥ 3 GU toxicity was very low in both treatment arms ranging 0.3-1.9% which might have masked the statistical significance. Many dosimetric studies to date (13) (14) (15) (16) 23 ) demonstrated a significant reduction of V 40 Gy of the bladder with IMRT planning compared to 3DCRT. Although minor acute GU toxicities are normally self-limited, using IMRT can further improve the quality of live and compliance of the patient undergoing NCRT for LARC. Due to the sensitivity of IMRT to geometric errors (34), one might be concerned of the risk of missing the target volume (14) , which can consequently affect oncologic outcomes. Using the National Cancer Database, Sun et al. recently reported that IMRT significantly increases the rate of positive margins and sphincter loss surgery compared to 3DCRT, without any perioperative or survival benefit in 7386 rectal cancer patients treated with NCRT, although toxicity profiles were not available (38) . Furthermore, the excess amount of cost caused by replacing 3DCRT with IMRT also has to be taken into consideration. However, selection biases may have masked the benefit of IMRT. For example, low-lying tumors which can result in higher rates of margin positivity and sphincter loss surgery may have been the major candidates of IMRT due to its superiority of reducing the doses to the genitalia (39) , aiming the preservation of sexual functions as well as reduced pain. It cannot be justified to reduce mild toxicity at the cost of significantly compromised oncologic outcomes, and therefore recommendation of IMRT routinely in all LARC patients cannot be concluded with the existing data. However, exquisite targeting of the tumor by using the available achievements of technical development such as image-guided RT with cone-beam computed tomography images can maximize the strength and therapeutic ratios of IMRT without compromised oncologic outcomes.
The results of our study harbor several limitations. First, all included studies were retrospective studies from various institutions. Second, the number of patients in the studied cohort was small in some studies (18) (19) (20) . Third, not all studies were available to be included for analysis for every endpoint. For example, only two studies were available for analysis regarding acute grade ≥ 3 proctitis (21,23) since no event occurred in both arms (IMRT and 3DCRT) from the study by Ng et al. (22) . For a broad endpoint, including only two studies for meta-analysis might result in a significantly biased conclusion. However, the endpoints in our study were very specific and two studies are regarded sufficient for metaanalysis (40) . No significant publication bias among studies was found although an Egger's regression test could not be performed for grade ≥ 3 proctitis. Furthermore, a weekly interview with the on-treatment patient is usual in most RT-facilities, which eliminates the possibility of bias in follow-up protocols for the evaluation of acute toxicity.
In summary, despite lack of evidence from randomized trials, IMRT seems to reduce acute GI toxicity and probably GU toxicity as well in LARC patients treated with 5-FU-based NCRT without compromised pCR rates. Currently, this study may serve as the strongest evidence for recommending IMRT in LARC patients.
